Navigation Links
Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:4/24/2008

- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 -

SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1 clinical trial of HspE7, its lead therapeutic candidate, in women with cervical intraepithelial neoplasia (CIN). Findings from the fourth cohort safety review demonstrated that HspE7 was safe and well tolerated with no serious adverse events being reported.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

An evaluation by the Safety Review Committee was performed after each of the four cohorts reached five weeks of treatment (two doses plus one week of follow-up). All of the patients in the Phase 1 study were administered 500 mcg of HspE7 with each of the four cohorts receiving escalating doses of adjuvant -- 50, 500, 1,000 and 2,000 mcg. The company previously announced that HspE7 was also well tolerated in the first three cohorts.

In addition to safety data, immunological data were collected from all patients pre-treatment, following each dose of HspE7 and at the end of the study. Preliminary evaluation of biological samples collected from the study's first and second cohorts indicates that administration of HspE7 results in an E7-specific T-cell immune response. Independent research findings published by Jeffrey Weber, M.D., Ph.D., in the journal Gynecologic Oncology demonstrate that such an immune response may be associated with objective clinical responses in patients with CIN. Therefore, Nventa believes that HspE7 may successfully treat CIN by activating and enhancing the body's natural immune system. The company expects to release immunological data from the third and fourth cohorts in the coming months.

"We are pleased with the broa
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
4. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
5. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
6. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
7. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
8. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
9. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
10. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
11. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... Biosystems and Berg Diagnostics, members of the Berg Pharma group ... Disorder (ASD) Biomarker Discovery Using the Berg Interrogative Biology ... in San Francisco, CA. The study was conducted by assessing ... where more than 1 child was afflicted by the disorder. ...
... ANN ARBOR, Mich., March 5, 2012  Neuroimaging for stroke patients ... nationwide for stroke care, according to University of Michigan research. ... found that 95 percent of stroke patients who received magnetic ... "Compared to CT, MRI is a more ...
Cached Medicine Technology:Berg Pharma Companies Present Groundbreaking Approach to Understanding Autism and Identify Novel Biomarkers That May be Crucial in Diagnosis 2Berg Pharma Companies Present Groundbreaking Approach to Understanding Autism and Identify Novel Biomarkers That May be Crucial in Diagnosis 3Physicians Order Costly, Redundant Neuroimaging for Stroke Patients, Study Says 2
(Date:12/25/2014)... December 25, 2014 Residents at ... Community, recently showed their generous spirit by providing ... Catawba County Parenting Network- Grandparents Raising Grandchildren program. ... gathered around the largest Christmas tree on the ... purchased by residents of the Abernethy Village Association ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A new, injectable ... and Drug Administration. The agency on Tuesday approved ... those who are overweight and have at least one ... 2 diabetes or high cholesterol. Patients taking the ... low-calorie diet and exercise regularly, the FDA noted. ...
Breaking Medicine News(10 mins):Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3
... of Catholics for Choice, issued the following statement on Respect ... Catholic Bishops holds its annual Respect Life Sunday. On this ... also respect the truth. A recent publication by the USCCB, ... on healthcare reform prove that the bishops, desire to promote ...
... , WILMINGTON, Del., Oct. 2 Nationwide Health ... of 4,000 production transactions processed through the NHIN ... CONNECT solution. , CONNECTfx was developed ... NHIEs, HIEs, and other collaborative healthcare organizations by ...
... NASHVILLE, Tenn., Oct. 2 Brookdale Senior Living Inc. (NYSE: ... Chief Financial Officer, will make a presentation regarding the Company ... New York on Monday, October 5, 2009, beginning at 3:30 ... live and can be accessed on the Internet at ...
... risk rises when transfused blood is more than 28 days old, ... suffered severe trauma and are given a major transfusion of red ... are twice as likely to die as those who receive fresher ... of 202 severe trauma patients who were treated with five or ...
... Oct. 2 Brent Phillips, a senior executive at ... officer of Aurora Medical Group. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ... the 960-physician medical group. , "Brent will ... Jeff Bailet, M.D., president of Aurora Medical Group. ...
... a long way in the last decade. Today, one can talk, ... even access the Web. Now imagine a cell phone that can ... test water quality after a major disaster like a hurricane or ... engineering at UCLA,s Henry Samueli School of Engineering and Applied Science, ...
Cached Medicine News:Health News:Respect Life and the Truth on Respect Life Sunday 2Health News:Respect Life and the Truth on Respect Life Sunday 3Health News:NHIT Processes Over 4,000 Production Transactions, Advances Adoption of NHIN Initiative 2Health News:Fresh Blood Boosts Survival in Trauma Patients 2Health News:Mayo Clinic Executive Brent Phillips to Join Aurora Medical Group as Chief Operating Officer 2Health News:NIH recognizes engineering professor's innovative research with major award 2Health News:NIH recognizes engineering professor's innovative research with major award 3
... completely digital camera system by KARL STORZ, ... endoscopic camera systems. Digital Source Sampling technology, ... the fully digital transfer of information with ... converter, as well as loss-free data storage ...
... Countless challenges. One complete solution. ... documentation. Instrument maintenance. Staff turnover. These are ... point-of-care professionals challenges that can impact ... your critically-ill patients. , , ...
... The Dornier Medilas D Fibertom is a 60 ... nm wavelength. The use of Diode Power Bar ... system ideal for endovenous laser treatment for varicose ... Medilas D Fibertom also includes unique safety features ...
... is a new High Magnification Slit-Lamp Biomicroscope. ... anterior segment diagnostics and documentation This highly ... to maintain, and very cost effective. The ... Magnification Slit-Lamp Biomicroscope available today. It can ...
Medicine Products: